Genenta Science S.p.A.

What they do

The company is a biological products developer with no approved products. It conducts research and development in gene therapy for cancer. Operations are based in Milan, Italy, with the ordinary shares and American depositary shares listed on the Nasdaq Capital Market. As a foreign private issuer, it files annual reports on Form 20-F.

Revenue drivers

• No product revenue — The company has no approved products and reports no revenue from product sales; all activity is research and development.
• Grant and other income — Any income is limited to grants or other non-product sources, as no commercial segment is described in the filing excerpts.

Recent performance

Net loss was $6.5M in 2025, narrowing from $8.9M in 2024 and $11.6M in 2023. Diluted EPS improved to -$0.33 in 2025 from -$0.49 in 2024 and -$0.64 in 2023. Operating cash flow was -$6.9M in 2025, compared with -$6.2M in 2024 and -$11.2M in 2023. At December 31, 2025, total assets were $31.9M and shareholder equity was $21.8M, with 23,432,183 ordinary shares outstanding.

Strategy

Management continues to fund research and development for gene therapies, with no commercial-stage products. The company relies on external financing to sustain operations, as cash flow from operations has been negative each year from 2021 through 2025. No specific pipeline milestones or partnership details are described in the provided excerpts.

Risks

• Clinical and regulatory risk — As a clinical-stage company with no approved products, success depends on obtaining regulatory approval for its gene therapy candidates.
• Funding and liquidity risk — The company has reported negative operating cash flow every year from 2021 to 2025, including -$6.9M in 2025, and may need to raise additional capital.
• Accumulated losses — Net losses totaled $40.9M over the five years from 2021 to 2025, and continued losses are likely before any product revenue.
• Foreign private issuer status — As an Italian company filing on Form 20-F, it is subject to different disclosure and governance requirements than U.S. domestic issuers.

Outlook

The filing excerpts do not contain management's specific guidance or expected milestones. The company's ability to continue as a going concern depends on future financing and clinical progress, but no forward-looking details are provided in the source material.